Vanguard Group Inc. boosted its stake in shares of PAREXEL International Corporation (NASDAQ:PRXL) by 0.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,205,566 shares of the medical research company’s stock after purchasing an additional 39,302 shares during the quarter. Vanguard Group Inc. owned approximately 8.28% of PAREXEL International Corporation worth $365,506,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in PRXL. Public Employees Retirement System of Ohio boosted its position in PAREXEL International Corporation by 4.5% during the 1st quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock valued at $108,000 after purchasing an additional 73 shares during the period. Invictus RG acquired a new position in PAREXEL International Corporation during the 1st quarter valued at approximately $158,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in PAREXEL International Corporation by 10.0% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock valued at $173,000 after purchasing an additional 180 shares during the period. BlueCrest Capital Management Ltd acquired a new position in PAREXEL International Corporation during the 1st quarter valued at approximately $202,000. Finally, Mogy Joel R Investment Counsel Inc. acquired a new position in PAREXEL International Corporation during the 2nd quarter valued at approximately $204,000. Institutional investors and hedge funds own 87.45% of the company’s stock.

PAREXEL International Corporation (NASDAQ PRXL) opened at 88.08 on Friday. The firm has a market cap of $4.50 billion, a price-to-earnings ratio of 42.76 and a beta of 0.77. PAREXEL International Corporation has a 12 month low of $51.16 and a 12 month high of $88.10. The firm’s 50-day moving average price is $87.85 and its 200-day moving average price is $79.27.

PAREXEL International Corporation (NASDAQ:PRXL) last released its quarterly earnings results on Monday, August 28th. The medical research company reported $1.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.08. PAREXEL International Corporation had a return on equity of 28.98% and a net margin of 4.49%. The firm had revenue of $557.20 million during the quarter, compared to analysts’ expectations of $537.59 million. During the same period last year, the firm posted $0.94 EPS. Equities research analysts predict that PAREXEL International Corporation will post $4.06 earnings per share for the current year.

A number of research firms recently issued reports on PRXL. Zacks Investment Research upgraded PAREXEL International Corporation from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research report on Tuesday, August 8th. Barclays PLC lowered PAREXEL International Corporation from an “overweighr” rating to an “equal weight” rating and set a $87.00 price objective for the company. in a research report on Tuesday, June 20th. Jefferies Group LLC restated a “hold” rating and set a $88.10 price objective on shares of PAREXEL International Corporation in a research report on Wednesday, June 21st. Raymond James Financial, Inc. upgraded PAREXEL International Corporation from an “underperform” rating to a “mkt perform” rating in a research report on Tuesday, June 20th. Finally, BidaskClub lowered PAREXEL International Corporation from a “strong-buy” rating to a “buy” rating in a research report on Friday, July 28th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and four have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $75.92.

TRADEMARK VIOLATION NOTICE: “Vanguard Group Inc. Has $365.51 Million Position in PAREXEL International Corporation (PRXL)” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/10/08/vanguard-group-inc-has-365-51-million-position-in-parexel-international-corporation-prxl.html.

About PAREXEL International Corporation

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Corporation (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International Corporation (NASDAQ:PRXL)

Receive News & Stock Ratings for PAREXEL International Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Corporation and related stocks with our FREE daily email newsletter.